In chronic granulomatous disease (CGD), defective phagocytic NADPH oxidase activity causes reduced superoxide anion (O 2 • ) radical production leading to frequent infections as well as granulomas and impaired wound healing indicative of excessive inflammation.
Based on recent mouse studies, the lack of O 2 • -dependent IFNγ-induced synthesis of kynurenine (kyn), an anti-inflammatory tryptophan metabolite produced by indolamine 2,3 deoxygenase (IDO), was proposed as a cause of hyperinflammation in CGD and this pathway has been considered for clinical intervention. Here, we show that IFNγ induces normal levels of kynurenine in cultures of O 2
• -deficient monocytes, DC, and PMN from gp91 PHOX -or p47 PHOX -deficient human CGD donors. Kynurenine accumulation was dose-and time-dependent as was that of a downstream metabolite, anthranilic acid.
Furthermore, urinary and serum levels of kynurenine and a variety of other tryptophan metabolites were elevated rather than suppressed in CGD donors. Although we did not specifically evaluate kyn metabolism in local tissue or inflamed sites in humans, our data demonstrates that O 2 • anion is dispensable for the rate-limiting step in tryptophan degradation, and CGD patients do not appear to have either hematopoietic cell or systemic deficits in the production of the anti-inflammatory kynurenine molecule.
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From . In these CGD mouse studies, the defective conversion of tryptophan into N-formylkynurenine by superoxide-dependent mouse IDO could be circumvented by providing exogenous kynurenine and IFNγ thereby dramatically reversing inflammation 8 . Consequently, the IDO-kynurenine pathway was rapidly proposed as a therapeutic target to control inflammation in human CGD
10
. Tryptophan and kynurenine are important immunoregulatory modulators of tolerance during pregnancy, infection, and autoimmunity
11
. While the bulk of systemic tryptophan 
Sample preparation and stimulation
PMN were isolated as previously described 15 and purity exceeded 90%. For the western blot experiments, PMN were further purified with MACS to a purity of 99%.
Monocytes were prepared using the Dynal Monocyte Negative Isolation bead kit, Invitrogen, mean 87% purity by FACS using CD45:FITC, CD14:PE, Beckton Dickenson). PMN and monocytes were suspended in 0.5 ml (5 x 10 6 /ml and 1x10 6 /ml, respectively) RPMI 1640/10% FCS/50 µM Trp and incubated with buffer or indicated doses of IFNγ (Actimmune) at 37°C and 5% CO 2 for the indicated periods of time.
Dendritic cells (generated from monocytes in RPMI1640, FCS, Pen/Strep/Lglutamine, 25mM HEPES, 1% non-essential amino acids, Sodium Pyruvate, and 50 nM 2-mercaptoethanol, with 50 ng IL-4/ml and 100U GM-CSF/ml added on day 3 for 7 days) were stimulated with IFNγ as described above.
Sera were collected in serum separator tubes and stored frozen until analysis.
Urine (24 hour collections) from two A-CGD, 4 X-CGD and three normal donors were stored frozen until analysis. 
ESI-MS) for Tryptophan and metabolites
Tryptophan, kynurenine, 3-hydroxy-kynurenine, α-picolinic acid, anthranilic acid, quinolinic acid, trichloroacetic acid (TCA) and heptafluorobutyric acid (HFBA) solutions were obtained from Sigma-Aldrich (St. Louis, MO, USA). Deuterated standards D5-tryptophan and D6-kynurenine were obtained from Cambridge Isotope Laboratories (Andover, MA, USA) and D4-picolinic acid was obtained from CDN Isotopes (PointeClaire, Quebec, Canada). Samples and/or standards were mixed for 10 minutes with a TCA solution containing deuterated tracers and centrifuged at 14,000 x g for 5 min.
LC-ESI-MS was performed with an Agilent 1200 system (Santa Clara, CA, USA) coupled to a Finnigan Quantum-AM triple quadrupole mass spectrometer (Thermo of the standards were as follows: tryptophan (2 nM), anthranilic acid (4 nM), kynurenine (9 nM), 3-hydroxy-kynurenine (9 nM), picolinic acid (10 nM), quinolinic acid (40 nM).
The general MS conditions were as follows: spray voltage, 4800 V; sheath and auxiliary For personal use only. on November 12, 2017. by guest www.bloodjournal.org From 7 gas, nitrogen; sheath gas pressure, 49 arbitrary units; auxiliary gas pressure, 25 arbitrary units; ion transfer capillary temperature, 350 ºC; collision gas pressure, argon; collision gas pressure, 1.5 mTorr; scan width, 0.70 u; scan time, 0.03s; Q1 peak width, 0.7 u fullwidth half-maximum (fwhm); Q3 peak width, 0.70 u fwhm. The collision energy voltage for PA, D4-PA, QA, 3-HKYN, KYN, D6-KYN, AA, TRP, and D5-TRP were 19, 19, 28, 18, 26, 26, 10, 21, and 21, respectively. The metabolite concentrations in the samples were calculated using a second order polynomial fit constructed by plotting the concentrations of standard metabolites vs. peak area ratios. The concentrations used were: 0.14, 0.41, 1.2, 3.7, 11, 33 and 100 µM. The peak area ratios were calculated by dividing the peak areas of metabolites by the deuterated internal standards (i.e., picolinic acid/D4-picolinic acid, quinolinic acid/D4-picolinic acid, 3-hydroxykynurenine/D6-kynurenine, kynurenine/D6-kynurenine, anthranilic acid/D6-kynurenine, tryptophan/D5-tryptophan). Billerica, MA) using a Trans-blot unit. After blocking with 5% nonfat dry milk in TBS for 2 h, the membranes were incubated overnight with a 1:3000 dilution (in 5% BSA) of anti-IDO antibody (clone EPR1230Y, Epitomics, Burlingame, CA), washed 3 times, and then incubated for 1 h with anti-rabbit IgG-HRP secondary antibody (GE Healthcare, Piscataway, NJ, 1:1000 in blocking buffer). Blots were developed using enhanced chemiluminescence (Bio-Rad, Hercules, CA) and visualized using the ChemiDoc XRS System (Bio-Rad). The membranes were then stripped (GM Biosciences, Frederick, MD) and re-probed with anti-actin antibody (Millipore, clone C4 1:10,000 in blocking buffer) and developed as described above.
IDO protein detection

Statistics
Statistical testing was by paired t-test employing a 2-tailed p-value or by non-parametric ANOVA (Kruskal-Wallis) performed using the GraphPad Prism 5.0b for Mac
Results:
Defects in gp91 PHOX -or p47 PHOX -were confirmed in these patients by gene sequencing (gp91 PHOX ) and western blot protein expression (gp91 PHOX and p47 PHOX ). To confirm the extent of functional impairment of the NADPH oxidase, PMA-induced O 2
• production by PMN was measured as previously described 15 by cytochrome C reduction resulting in values (in units of nmoles/10 6 PMN/60 minutes) of 1.77±0.58 for A-CGD (mean ± SD, n=3) and 2.02±1.79 for X-CGD (n=5) versus a reference value for normal PMN of 232.55±57.14 (n=170).
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Interferon-γ induction of indoleamine 2,3-dioxygenase (IDO) protein in normal and
CGD leukocytes
To confirm that human monocytes and PMN from CGD patients were capable of producing IDO, the initial enzyme in the kynurenine synthesis pathway 11 , we treated cells with different doses of IFNγ and detected IDO with specific antibodies by western blotting. As shown in Figure 1 , the level of IDO increased both in normal and CGD monocytes. Highly purified PMN were also found to upregulate expression of IDO protein following IFNγ-treatment and no difference was noted between normal and CGD cells however the amount of IDO expressed by PMN appeared to be at least 5-times less than that expressed by monocytes.
Indoleamine 2,3-dioxygenase (IDO) enzymatic activity in normal and CGD leukocytes
To detect tryptophan metabolites, we used a LC-ESI-MS to measure their concentrations in cell culture supernatants, serum, and urine. As shown in Figure 2 , simultaneous detection of several metabolites was possible with this technique (sensitivities listed in methods).
We next examined the IFNγ dose-dependence of tryptophan metabolism in normal and CGD monocytes. As shown in Figure 3 , all donor groups appeared to respond near maximally to IFNγ doses of as low as 100 IU/ml in terms of depletion of tryptophan ( Figure 3A ) and accumulation of kynurenine ( Figure 3B ) and anthranilic acid ( Figure 3C ) in culture supernatants. Another cell type implicated in regulation of inflammation are dendritic cells. We therefore tested whether monocyte-derived dendritic cells were capable of tryptophan catabolism. As shown in Figure 5 , no difference was detected between normal and CGD MDDC in terms of kynurenine accumulation which was inversely proportional to the amount of detected tryptophan.
Systemic tryptophan metabolism in CGD 1 1
We demonstrated normal tryptophan metabolism in leukocytes from human CGD donors however we were unable to detect other known downstream metabolites (with the exception of anthranilic acid) in culture supernatants from either normal or CGD cells unless we supplemented media with supraphysiologic concentrations of tryptophan.
Although systemic tryptophan metabolism relies predominantly on hepatic enzymes such as tryptophan 2,3 dioxygenase, we tested sera from our patients for these metabolites.
Kynurenine concentrations in sera from CGD patients were significantly higher than We therefore tested 24 hour urine samples from normal donors and 2 A-CGD and 4 X-CGD donors. For most urinary tryptophan metabolites tested, levels in CGD patients were the same or elevated compared to normal controls ( Figure 6 ). Quinolinic acid was undetectable in normal urine but was detected in urine from CGD donors.
Discussion:
CGD is an inherited disease caused by defects in components of the NADPH oxidase that lead to defective superoxide production. In addition to recurrent infections, a major component of CGD is the exuberant hyperinflammation leading to the characteristic chronic granulomas, delayed wound healing, and autoimmunity. The mechanism(s) underlying the dysregulated inflammation in CGD remains unclear.
For
Recent studies with p47 PHOX -knockout mice attributed this hyperinflammatory state to the absence of superoxide-dependent IDO activity 8 and offered hopes of phenotypic reversal with supplementary kynurenine and IFNγ.
We found, as had previously been reported 8, 17, 18 , that IFNγ dramatically increased the concentration of kynurenine and decreased that of tryptophan in culture supernatants from normal human monocytes (Figures 3 and 4) . Kynurenine production could also be for the difference between our results and those reported in mouse CGD is that in the latter case, lung homogenates and isolated phagocytes from infected mice were studied8.
Our studies with human subjects however demonstrated that both the magnitude and rate of kynurenine accumulation in culture supernatants of human peripheral blood leukocytes is independent of O 2 • .
Since the bulk of systemic tryptophan conversion is performed by the constitutively expressed hepatic tryptophan 2,3-dioxygenase enzyme (TDO), isolated human CGD cells may not reveal a systemic defect in tryptophan metabolism. We therefore measured levels of tryptophan and some of its major metabolites in serum and urine from normal and CGD donors. In no case did CGD appear to decrease the levels of these metabolites, on the contrary the concentrations of these molecules were higher in urine from CGD donors than from normals. While it is possible that superoxide may be required to further catabolize these metabolites and that levels are increased due to substrate accumulation, a more likely explanation is that the increased levels of infection and inflammation in these patients has caused an upregulation of this pathway. A study published in 1970 similarly reported an increase in the urine concentrations of kynurenine and 3-OH kynurenine 16 , although this early work did not report levels for other metabolites we report here. Taken together, these results reveal normal or elevated tryptophan metabolite levels in CGD patients. Since both IDO and TDO metabolize tryptophan, the serum kynurenine levels may not reflect IDO activity at a systemic level.
However, in the in vitro PMN and MNC system, the elevated kynurenine levels correlated with increased IDO expression with IFNγ induction.
The results shown here suggest a difference in the regulation of human and mouse IDO enzymatic activity in leukocytes. In CGD mice, the absence of O 2 • prevents the activation of murine IDO, thus preventing kynurenine accumulation resulting in an excess of IL17 production from unrestrained γd-T cell activity giving rise to a hyperinflammatory phenotype 8 . Furthermore, the absence of kynurenine production in mouse also decreases the levels of a variety of downstream kynurenine metabolites that likely play important roles in regulating inflammation. 3 .
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